Executive Medical Director, Multiple Myeloma Lead

Summit Strategic Search•Somerville, NJ

21h•Hybrid

About The Position

The Executive Medical Director will serve as the clinical lead for the company's Multiple Myeloma pipeline within the Clinical Development organization. This role provides strategic, scientific, and medical leadership across a portfolio of assets, shaping the myeloma strategy and delivering integrated clinical development plans from first-in-human studies through proof-of-concept and, where appropriate, later-stage development and potential registration. The position spans first-in-human, dose-escalation, dose-expansion, and proof-of-concept studies. It supports IND submissions and regulatory interactions and integrates translational, biomarker, pharmacology, and safety data to inform pipeline decisions, differentiation, and benefit-risk assessment. The leader will work in a fast-paced, highly matrixed environment and supervise clinical development medical directors and clinical science staff supporting the pipeline. This is a full-time, permanent, direct-hire position based in Central New Jersey with a hybrid workplace structure. The role requires travel of up to 15% to 20% of the time. Compensation is $350,000–$405,000 base salary, plus a target annual bonus, long-term incentive eligibility, and a new-hire equity grant.

Requirements

MD, MD-PhD, or equivalent medical degree.
Board certification in hematology or oncology.
At least 6 years of clinical development experience in the biopharmaceutical industry and/or academic medicine, with substantial experience in hematologic malignancies and multiple myeloma.
Demonstrated experience designing and leading early clinical development programs, including first-in-human studies, dose escalation and expansion, dose selection, integrated safety monitoring, clinical data review, and proof-of-concept generation.
Strong understanding of multiple myeloma clinical development, including IMWG response criteria, measurable residual disease, safety monitoring, benefit-risk evaluation, dose optimization, biomarker strategy, and development decision-making.
Ability to translate complex medical, scientific, translational, regulatory, and competitive information into clear clinical development strategies and actionable plans.
Excellent written and verbal communication skills, including developing clinical and regulatory documents, presenting to senior leaders, and engaging external experts and investigators.
Strong collaboration, influencing, conflict-management, negotiation, and decision-making skills, with the ability to align stakeholders across functions, geographies, and organizational levels.
Ability to anticipate and integrate needs from clinical operations, regulatory, safety and pharmacovigilance, biometrics, translational science, project management, CMC, and other development functions.
Track record of delivering results in a fast-paced environment and ability to operate strategically while contributing hands-on when needed.
Commitment to high standards of quality, ethics, compliance, patient safety, and professional conduct.
Ability to travel up to 15% to 20% of the time.

Nice To Haves

Multiple myeloma clinical development experience across relapsed/refractory and earlier-line settings.
Experience with cell therapy, CAR-T, in vivo cell therapy, T-cell engagers, bispecific antibodies, antibody-drug conjugates, protein degraders, or other novel modalities for myeloma.
Experience leading or contributing to pipelines with multiple assets, indications, or lifecycle opportunities, including pipeline governance, prioritization, and investment decisions.
Experience contributing to IND submissions, pre-IND or IND meetings, regulatory briefing packages, and health authority interactions.
Experience leading or significantly contributing to cross-functional development teams in a matrixed, global environment.

Responsibilities

Serve as clinical lead for the Multiple Myeloma pipeline and provide strategic, scientific, and medical leadership across the development lifecycle.
Develop and execute integrated clinical development plans, including disease setting and line of therapy, patient population, endpoints, dose selection, combination strategy, biomarker and MRD strategy, safety monitoring, and evidence generation.
Drive pipeline prioritization, asset sequencing, and stage-gate decisions using data-driven criteria for advancing, pausing, or terminating assets.
Identify opportunities to differentiate and expand the pipeline through novel targets, treatment modalities, combinations, and sequencing; contribute clinical expertise to business development and due diligence.
Represent the pipeline in internal governance forums, senior leadership reviews, external scientific meetings, regulatory interactions, and partnership discussions as needed.
Lead the design, execution, monitoring, interpretation, and reporting of first-in-human, dose-escalation, dose-expansion, proof-of-concept, and other early clinical studies in multiple myeloma.
Lead or contribute to later-stage development activities when appropriate, including pivotal study strategy, comparator and endpoint selection, protocol design, data interpretation, and registration-enabling planning.
Provide medical and scientific oversight of study conduct, including medical monitoring, eligibility review, safety review, dose-escalation decisions, and interpretation of emerging clinical data.
Ensure early development plans reflect contemporary regulatory expectations, including dose optimization, PK/PD integration, biomarker-informed decisions, and clear benefit-risk assessment.
Provide clinical leadership for protocols, clinical study reports, investigator brochures, regulatory briefing documents, IND submissions, health authority meeting packages, publications, abstracts, and presentations.
Identify pipeline risks and mitigation strategies across clinical, regulatory, operational, safety, competitive, and translational areas.
Partner with cross-functional colleagues in translational science, biomarkers, pharmacology, nonclinical, regulatory, safety and pharmacovigilance, biostatistics, data management, clinical operations, project management, CMC, business development, and commercial functions.
Engage investigators, academic experts, cooperative groups, study sites, patient advocacy organizations, and external advisors to support execution, scientific exchange, enrollment strategy, and visibility in the myeloma community.
Provide leadership and supervision to clinical development medical directors and clinical science staff supporting the pipeline.
Champion patient focus, scientific rigor, collaboration, urgency, ethics, compliance, and operational excellence.